A Phase 1, Randomized, Single-center, Single-dose, Double-blind, Placebo-controlled Pharmacokinetic, Safety, and Pharmacodynamic Study of Subcutaneous Injection of 160 microg/kg, 240 microg/kg, and 400 microg/kg Plerixafor in Healthy Adult Volunteers of Japanese Descent

Trial Profile

A Phase 1, Randomized, Single-center, Single-dose, Double-blind, Placebo-controlled Pharmacokinetic, Safety, and Pharmacodynamic Study of Subcutaneous Injection of 160 microg/kg, 240 microg/kg, and 400 microg/kg Plerixafor in Healthy Adult Volunteers of Japanese Descent

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • Focus Pharmacokinetics
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 29 Jun 2012 Actual completion date (February 2012) added as reported by ClinicalTrials.gov.
    • 29 Jun 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top